HOWL · Werewolf Therapeutics, Inc. · Proposed Sales
$1.10
+0.06 (+5.77%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report. We are currently evaluating strategies to raise additional capital, however, there can be no assurances that we will be successful in mitigating the conditions which raise substantial doubt about our ability to continue as a going concern in the near term, if at all.”View the 10-Q filed Jul 31, 2026
Market Cap
$50.54M
Shares
48.60M
Volume · Oct 20
484.16K
Avg daily vol (3M)
6.69M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-01-06 | MPM BioVentures 2014, L.P. | Shareholder | 198,739 | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM Asset Management LLC | Shareholder | 31,458 | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | UBS Oncology Impact Fund, L.P. | Shareholder | 164,126 | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM BioVentures 2014 (B), L.P. | Shareholder | 13,256 | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM Asset Management Investors BV2014 LLC | Shareholder | 6,840 | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM Oncology Innovations Fund, L.P. | Shareholder | 43,767 | 2026-01-06 | Merrill Lynch |
| 2025-12-29 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM BioVentures 2014, L.P. | Shareholder | 130,125 | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM BioVentures 2014 (B), L.P. | Shareholder | 8,679 | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM Asset Management Investors BV2014 LLC | Shareholder | 4,479 | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM Asset Management LLC | Shareholder | 20,597 | 2025-12-29 | Merrill Lynch |
| 2025-12-22 | MPM BioVentures 2014, L.P. | Shareholder | 130,125 | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM Asset Management Investors BV2014 LLC | Shareholder | 4,479 | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM Asset Management LLC | Shareholder | 20,597 | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM BioVentures 2014 (B), L.P. | Shareholder | 8,679 | 2025-12-22 | Merrill Lynch |
| 2025-12-10 | MPM BioVentures 2014 (B), L.P. | Shareholder | 5,912 | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | UBS Oncology Impact Fund, L.P. | Shareholder | 73,195 | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM BioVentures 2014, L.P. | Shareholder | 88,632 | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM Asset Management LLC | Shareholder | 14,029 | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM Oncology Innovations Fund, L.P. | Shareholder | 19,519 | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM Asset Management Investors BV2014 LLC | Shareholder | 3,050 | 2025-12-10 | Merrill Lynch |
| 2025-12-03 | MPM BioVentures 2014 (B), L.P. | Shareholder | 8,679 | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM BioVentures 2014, L.P. | Shareholder | 130,125 | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM Asset Management Investors BV2014 LLC | Shareholder | 4,479 | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM Asset Management LLC | Shareholder | 20,597 | 2025-12-03 | Merrill Lynch |
| 2025-11-24 | MPM Asset Management Investors BV2014 LLC | Shareholder | 4,479 | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM Asset Management LLC | Shareholder | 20,597 | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM BioVentures 2014, L.P. | Shareholder | 130,125 | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM BioVentures 2014 (B), L.P. | Shareholder | 8,679 | 2025-11-24 | Merrill Lynch |
| 2025-11-17 | MPM BioVentures 2014, L.P. | Shareholder | 130,125 | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM Asset Management LLC | Shareholder | 20,597 | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM BioVentures 2014 (B), L.P. | Shareholder | 8,679 | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM Asset Management Investors BV2014 LLC | Shareholder | 4,479 | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-11-17 | Merrill Lynch |
| 2025-11-10 | MPM BioVentures 2014, L.P. | Shareholder | 130,125 | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM Asset Management Investors BV2014 LLC | Shareholder | 4,479 | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM Asset Management LLC | Shareholder | 20,597 | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM BioVentures 2014 (B), L.P. | Shareholder | 8,679 | 2025-11-10 | Merrill Lynch |
| 2025-11-04 | UBS Oncology Impact Fund, L.P. | Shareholder | 107,463 | 2025-11-04 | Merrill Lynch |
| 2025-11-04 | MPM Oncology Innovations Fund, L.P. | Shareholder | 28,657 | 2025-11-04 | Merrill Lynch |
Showing 1–50 of 66 filings